FDA okays trial of novel allogenic cell therapy for COVID-19 linked ARDS
HOUSTON-- The US Food & Drug Administration (FDA) has cleared the way to initiate a Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatment of COVID-19 associated acute respiratory distress syndrome (ARDS).
Cellenkos Inc.a privately held, clinical stage biotech company has been authorized to conduct the trial.The trial is designed as a randomized, double-blinded, placebo-controlled study to assess safety and preliminary efficacy in this hospitalized patient population.
CK0802 is a novel allogenic cell therapy product consisting of Treg cells derived from clinical-grade umbilical cord blood units and manufactured using Cellenkos' proprietary process.
Treg cells in CK0802 express lung homing markers on their cell surfaces. Once the cells reach the tissue, Treg cells are believed to disarm and damp down the cytokine storm by engaging with antigen-presenting cells including the pneumocytes that line the alveolar epithelium and drive the inflammatory reaction.
"We appreciate FDA's expedited review of our plans to evaluate CK0802 in critically ill, intubated patients suffering from ARDS, a deadly complication of COVID-19", said Elizabeth J Read, MD, Chief Technology Officer, Cellenkos Inc. "Preliminary observations in two intubated COVID-19 ARDS patients, who received cryopreserved cord blood T-regulatory cells under FDA Emergency Use Authorization after failing tociluzumab, were promising. In the forthcoming Phase 1 randomized trial, CK0802 will be assessed for both toxicity and 28-day treatment success, as co-primary outcomes."
"Use of allogeneic, off-the-shelf cord blood-derived T-regulatory cells has emerged as a promising therapeutic strategy for the treatment of inflammatory disorders, specifically in terms of interrupting and arresting the cytokine storm unleashed by COVID-19 infection," said Dr Siddhartha Mukherjee, MD, PhD, Columbia University, New York, scientific advisor and collaborator on the multi-center clinical trial. "Rather than indiscriminate therapy with a drug such as an inhibitor of single cytokine such as IL-6, the T-regulatory cells can potentially calm inflammation exactly where it is most active, without causing a more general "global" immunosuppression that would be harmful in a virally infected patient. Planned correlative assays during the clinical trial will provide insights into the mechanism of action of CK0802 and its relation to clinical outcomes."
"This is a great milestone for our company and highlights our core strength in rapid scale up and manufacture of novel cellular products", said Tara Sadeghi, VP, Clinical Operations at Cellenkos Inc. "CK0802 is an off-the-shelf, allogeneic T-regulatory cell product that is cryopreserved, shipped to the clinical site and infused at the patient's bedside. We are very excited to bring forward this promising, potentially life-saving therapy and look forward to contribute to the growing therapeutic armamentarium for COVID-19."
Since 2017, the company has owned and operated an independent ISO-7 cleanroom manufacturing facility in Houston, engaged in process development and manufacture of clinical cell therapy products, including testing and quality control. Staffed with experienced personnel, the facility is equipped to support product supply for the clinical trials. Cellenkos already holds two FDA INDs for inflammatory bone marrow failure syndromes and demyelinating polyneuropathy. Cellenkos' CK0801 cell therapy product has demonstrated a high degree of safety in bone marrow failure syndromes, in the first two dose level cohorts completed to date (NCT03773393).
For more information, please visit www.cellenkosinc.com.
SOURCE Cellenkos, Inc.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd